Zyme Biosciences, a team led by Dr Marta Broto Aviles who is an i-sense postdoc in Prof Molly Stevens group at Imperial College London, have made the finals of WE Innovate 2021. The scheme is led by the Imperial Enterprise Lab and provides a platform to showcase the incredible progress being made in women’s entrepreneurship at Imperial – with winning teams receiving a part of a 30K prize fund for their ideas.
New research from the i-sense group at UCL, published in Biosensors and Bioelectronics, addresses the urgent need for more accurate rapid diagnostics for COVID-19 by developing an isothermal test that simultaneously detects two gene targets.
The quantum sensing abilities of nanodiamonds can be used to improve the sensitivity of paper-based diagnostic tests, potentially allowing for earlier detection of diseases such as HIV, according to a study led by researchers in the i-sense McKendry group at UCL.
Antibiotic resistence is a growing global concern and major threat to human health.
The standard method used to detect resistance in bacteria, known as phenotypic antibiotic sensitivity testing, monitors bacterial growth over about 12 – 24 hours and is therefore a slow process. New rapid methods for antibiotic sensitivity testing are urgently needed to improve antibiotic stewardship.
The team at i-sense have been working collaboratively across institutions to develop point-of-care diagnostic tests for COVID-19. When the UK went into lockdown in mid-March, a small group of researchers were given special access to i-sense labs in London and quickly implemented appropriate measures to ensure they could continue this important work safely.
Professor Molly Stevens’ team have been awarded £50,000 in funding from the new Imperial College COVID-19 Response Fund to develop point-of-care diagnostics for the current pandemic.
Led by Prof Molly Stevens, the i-sense team at Imperial College London have received over €500,000 in funding from the European Institute of Innovation and Technology (EIT) as part of their COVID-19 Rapid Response Call.
i-sense research into connected diagnostics was highlighted at the World Economic Forum this year by i-sense Deputy Director, Prof Molly Stevens.
The combination of mobile devices with diagnostic tools offers new possibilities to test, track and treat infectious diseases as well as improve health systems, according to a new review published today in Nature.
A new review from i-sense members, published in AIDS, looks at the last 20 years of research around diagnostics that use p24, an important protein in the detection of early stage HIV.
